|
Ezetimibe is a new important lowering blood ester drugs , since its listing in 2002 , sales increased year by year , but the synthesis of the drug steps long , low yield, high cost disadvantage cause this drug on the market because the drug has good development prospects and economic value of our group in the access and an abundance of literature on the basis of their synthesis has been optimized in order to achieve a simplified route , increase yield and reduce costs with similar drugs are more expensive ; the purpose , on this basis , we chose a relatively easy route was further optimized , and achieved good results .
|